Info

GeneSegues is a biopharmaceutical company built upon advanced, targeted drug delivery technology. We conduct research and early-stage development of proprietary oncology biopharmaceuticals using our ligand-directed, nanoencapsulation technology. Our two initial product candidates are antisense therapeutics for treatment of advanced head neck and prostate cancers. We are currently conducting animal experiments with our lead product candidate for head neck cancer, and in vitro experiments with our product candidate for prostate cancer. As we progress, we will seek to outlicense these therapeutic candidates to larger drug companies for later-stage development and post-approval marketing. We have shown our targeted nanoencapsulation technology can also be adapted to other commercially significant applications, such as tumor imaging and cardiovascular disease, as future business strategy may warrant. GeneSegues was founded in 1999. We are a privately-held company based in Minneapolis, Minnesota. The Company's funding includes grant awards from the National Cancer Institute, the Department of Defense, and the National Institute of Allergy and Infectious Diseases, and private investment. Our research has been presented at several national science conferences, including the American Association for Cancer Research annual conference held in Anaheim, California in April 2005.